Immutep (IMMP) vs Kyntra Bio (KYNB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Immutep (IMMP) has outperformed Kyntra Bio (KYNB) over the past year, gaining 78.8% versus a loss of 44.3%. Over five years, IMMP leads with a -8.1% price change compared with -97.8% for KYNB. Immutep is the larger company by market cap ($26.7 million vs $24.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMP | KYNB |
|---|---|---|
| Share price | $3.63 | $6.11 |
| Market cap | $26.75M | $24.74M |
| 1-day change | -5.47% | +2.52% |
| YTD return | +26.92% | -30.41% |
| 1-year return | +78.82% | -44.25% |
| 5-year return | -8.10% | -97.79% |
| EPS (TTM) | $-7.30 | $-7.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $70.60 | $11.65 |
| 52-week low | $3.55 | $5.62 |
| Distance from 52-week high | -94.86% | -47.55% |
| Analyst consensus | none | none |
| Avg. price target upside | +726.45% | +549.26% |
| Average volume | 15.06K | 18.02K |
| Shares outstanding | 7.37M | 4.05M |
| Employees | — | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMP has outperformed KYNB by 123.1 percentage points over the past year.
About Immutep
IMMP stock →Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations
About Kyntra Bio
KYNB stock →Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
IMMP vs KYNB FAQ
Which is bigger, Immutep or Kyntra Bio?
Immutep (IMMP) is larger, with a market capitalization of $26.75M compared with $24.74M for Kyntra Bio (KYNB).
Which stock has performed better over the past year, IMMP or KYNB?
IMMP returned +78.82% over the past 12 months, compared with -44.25% for KYNB (price return, excluding dividends). Past performance does not predict future results.
Are Immutep and Kyntra Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.